A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Phase 4 Completed 24 enrolled Watson Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.

Timeline

Start: 2004-12
Primary completion: 2005-12
Completion: 2008-05

Publications

Results Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxybutynin	Small molecule	3.9 mg	Other
Subject	Oxybutynin	Small molecule	7.8 mg	Other
Subject	Oxybutynin	Small molecule	9.1 mg	Other
Subject	Oxybutynin	Small molecule	11.7 mg	Other

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Summary

Timeline

Publications

Drugs

Indications